Compare McKesson Corporation (MCK) vs Procter & Gamble Co (PG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Procter & Gamble Co — how do they compare? McKesson Corporation trades at $829.24 (market cap $97.35B), while Procter & Gamble Co trades at $147.79 (market cap $347.26B). The key difference: Procter & Gamble Co is far larger — about 3.6× McKesson Corporation's market cap, and Procter & Gamble Co pays the higher dividend (2.92%). Which is the better fit depends on your goals.
| MCK | PG | |
|---|---|---|
Market Cap | $97.35B | $347.26B |
Sector | Health | Consumer Staples |
52-Week High | $995.69 | $167.18 |
52-Week Low | $659.01 | $138.10 |
Enterprise Value | $101.98B | $372.74B |
Dividend Yield | 0.39% | 2.92% |
Volume | — | 6,423,436 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $831.60, down 1.16% on the day, with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The stock shows strong analyst support with an 80% buy rating and a consensus price target of $932.83, implying potential upside. Revenue growth is robust, reaching $359.05 billion in 2025, though net margins remain thin at 1.18%. Cash flow from operations improved to $6.09 billion in 2025, supporting financial stability.
The outlook for MCK is positive, driven by earnings beats, analyst optimism, and solid cash generation. Key opportunities include growth in specialty pharma and oncology services. Risks involve policy uncertainties, competitive pressures, and execution challenges. The stock's current price near key support at $829 suggests a critical level for near-term direction.
Procter & Gamble (PG) trades at $148.00, down 1.31% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported consistent earnings beats in recent quarters, with Q2 2026 EPS expected at $1.41. Revenue reached $84.28 billion in 2025, with a net income margin of 19.16%. Recent developments include a partnership with the WNBA and ongoing dividend payments.
PG offers stable growth and reliable dividends, supported by strong cash flow and a 69-year dividend increase streak. Risks include premium valuation multiples and soft demand pressures. Analyst consensus is bullish with a $161.71 price target, suggesting potential upside from current levels amid moderate market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →
